Welcome to our dedicated page for REGENERON PHARMACEUTICALS SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.